Carisma Therapeutics Inc.

NASDAQ: CARM · Real-Time Price · USD
0.45
-0.05 (-10.41%)
At close: Jun 20, 2025, 3:59 PM

Carisma Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
16.23M 19.63M 20.27M 20.71M 15.07M 14.92M 14.36M 13.11M 12.26M 9.83M 26.1M 23.52M 23.06M 26.54M 6.54M 17.78M 15.55M
Cost of Revenue
924K 2.62M 4.03M 4.73M 5.19M 4.2M 20.2M 35.06M 34.35M 33.65M 15.58M 34K 8.04M 16.04M 16.03M 16.02M 8.01M
Gross Profit
15.31M 17.02M 16.24M 15.98M 9.89M 10.72M -5.84M -21.95M -22.09M -23.82M 10.52M 23.49M 15.01M 10.5M -9.49M 1.76M 7.54M
Operating Income
-42.67M -62.18M -66.77M -75.97M -85.27M -88.73M -75.14M -69.55M -62.51M -49.7M -36.48M -33.39M -31.26M -28.16M -47.22M -55.03M -69.58M
Interest Income
n/a n/a 1.29M 2.24M 3.41M 4.89M 5.45M 5.42M 4.24M 3.32M 1.47M 557K 557K n/a n/a n/a n/a
Pretax Income
-50.77M -60.48M -64M -72.7M -81.32M -86.88M -45.66M -42.59M -37.65M -24.43M -35.54M 45.9M 35.3M -8.61M -32.25M -116.84M -117.74M
Net Income
-50.77M -60.48M -63.8M -72.5M -81.22M -86.88M -53.61M -50.53M -41.63M -30.02M -33.38M 56.57M 42.1M -388K -24.34M -118.57M -119.47M
Selling & General & Admin
20.34M 20.19M 19.5M 20.92M 21.62M 27.44M 29.28M 26.43M 22.85M 15.49M 17M 21.93M 26.31M 29.39M 24.22M 19.63M 16.15M
Research & Development
51.37M 59.67M 63.51M 71.73M 74.95M 74.13M 55.67M 51.67M 47.37M 39.49M 45.56M 34.96M 27.95M 25.23M 23.77M 29M 26.37M
Other Expenses
-15.31M -15.31M -15.31M -15.31M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
71.71M 79.86M 83.01M 92.65M 96.56M 101.57M 84.95M 78.11M 70.22M 54.98M 62.57M 56.9M 54.26M 54.62M 47.98M 48.64M 42.52M
Interest Expense
508K 1.04M 1.33M 1.33M 823K 1.94M 1.65M 1.65M 6.58M 6.09M 6.09M 6.09M 1.16M n/a n/a n/a n/a
Selling & Marketing Expenses
-255K -1.95M -4.03M -4.03M -3.78M -2.08M n/a n/a n/a n/a 6.04M 13.06M 18.78M 22.99M 16.95M 9.92M 4.21M
Cost & Expenses
62.8M 85.71M 87.04M 96.68M 100.34M 103.65M 84.95M 78.11M 70.22M 54.98M 62.58M 56.92M 54.31M 54.71M 48.06M 48.7M 42.55M
Income Tax Expense
n/a 1.65M 1.45M 757.72K 845.72K -695K 7.25M 7.27M 3.31M 4.91M -2.84M -10.72M -6.85M -8.27M -7.96M 1.73M 1.71M
Shares Outstanding (Basic)
41.54M 41.46M 41.54M 41.54M 40.94M 40.39M 40.29M 40.26M 12.78M 10.14M 40.25M 9.97M 40.25M 9.97M 9.84M 8.77M 7.85M
Shares Outstanding (Diluted)
41.54M 41.46M 41.54M 41.54M 40.94M 40.39M 40.29M 40.26M 12.78M 10.14M 40.25M 9.97M 40.25M 9.97M 10.05M 8.77M 7.85M
EPS (Basic)
-1.22 -1.46 -1.56 -1.78 -2 -3.47 -1.74 -1.67 -2.28 -0.67 -0.98 6.76 4.96 -1.79 -5.24 -16.36 -18.14
EPS (Diluted)
-1.22 -1.46 -1.56 -1.78 -2 -3.47 -1.74 -1.67 -2.28 -0.67 -0.98 6.61 4.81 -1.94 -5.39 -16.36 -18.14
EBITDA
-40.79M -58.6M -64.01M -73.25M -82.08M -86.53M -78.78M -73.16M -66.6M -54.27M -30.7M 48.45M 36.73M -8.53M -32.15M -116.71M -117.62M
EBIT
-42.45M -61.96M -66.77M -75.97M -85.27M -88.73M -83.52M -77.93M -70.9M -58.08M -31.9M 47.97M 36.46M -8.61M -32.25M -116.84M -117.74M
Depreciation & Amortization
1.66M 3.35M 4.77M 4.73M 5.19M 4.2M 2.82M 2.85M 2.14M 1.44M 749K 34K 65K 85K 104K 125K 121K